| Home | E-Submission | Sitemap | Contact Us |  
JPTM > Ahead-of Print

doi: https://doi.org/10.4132/jptm.2019.04.16    [Epub ahead of print]
Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer
So Young Kim1, Kyung Un Choi2, Chung Su Hwang1, Hyung Jung Lee1, Jung Hee Lee1, Dong Hoon Shin1, Jee Yeon Kim1, Mee Young Sol1, Jae Ho Kim3, Ki Hyung Kim4, Dong Soo suh4, Byung Su Kwon4
1Department of Pathology, Pusan National University Yangsan Hospital, Yangsan, Korea
2Department of Pathology, Busan National University Hospital, Busan, Korea
3Department of Physiology, Pusan National University School of Medicine, Yangsan, Korea
4Department of Obstetrics and Gynecology, Busan National University Hospital, Busan, Korea
Corresponding Author: Kyung Un Choi ,Tel: +82-51-510-8055, Email: kuchoi@pusan.ac.kr
Received: December 26, 2018;  Revised: March 17, 2019  Accepted: April 16, 2019.  Published online: May 2, 2019.

Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis of the patients.
Immunohistochemical staining for CD109 and Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recur after chemotherapy.
CD109 expression was associated with overall survival (p = 0.02), but not recurrence-free survival (p = 0.29). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio [HR], 1.58; p = 0.16; 95% confidence interval [CI], 0.82–3.05) Although We found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = 0.047). Also, The CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = 0.001).
Examining the CD109 expression in patients with OEC may be helpful in predicting survival and the chemotherapeutic effect.
Key Words: Ovarian epithelial cancer, CD109, prognosis